Department of the Second Gynecologic Oncology, The First Affiliated Hospital of Henan Polytechnic University (The Second People's Hospital of Jiaozuo), Jiaozuo, Henan, 454000, China.
Immunotherapy. 2023 Aug;15(12):905-912. doi: 10.2217/imt-2023-0020. Epub 2023 Jun 21.
We present a case of a 76-year-old patient with recurrent cervical cancer who underwent first-line treatment with penpulimab combined with anlotinib. The patient was diagnosed with poorly differentiated stage III C1r cervical squamous cell carcinoma and received standard cisplatin-sensitized chemoradiotherapy, subsequently achieving a good treatment effect of complete response. Recurrence occurred nearly 14 months after treatment, with multiple metastases including in the brain and lung. Oral anlotinib was less effective, but the treatment of penpulimab combined with anlotinib showed an obvious curative effect. It has been maintained for more than 17 months, and as of April 2023 the patient is still maintaining her response. Our case suggests that penpulimab combined with anlotinib has promising efficacy in the treatment of elderly patients with recurrent cervical cancer.
我们报告了一例 76 岁复发性宫颈癌患者，该患者接受了派安普利单抗联合安罗替尼的一线治疗。该患者被诊断为分化差的 III C1r 期宫颈鳞状细胞癌，接受了标准顺铂增敏放化疗，随后获得了完全缓解的良好治疗效果。治疗后近 14 个月复发，出现包括脑和肺在内的多处转移。口服安罗替尼效果不佳，但派安普利单抗联合安罗替尼治疗显示出明显疗效。目前已维持治疗 17 个月以上，截至 2023 年 4 月，患者仍保持缓解。我们的病例表明，派安普利单抗联合安罗替尼在治疗老年复发性宫颈癌患者方面具有良好的疗效。
